CanSino Biologics Gets China Trial Approval to Expand Vaccine's Booster Age Range
MT Newswires Live
Yesterday
CanSino Biologics (HKG:6185) received approval from China's National Medical Products Administration to begin a clinical trial of its Td5cp combined vaccine in children aged four to five, according to a Monday Hong Kong bourse filing.
The trial will assess whether the vaccine can be used as a booster in children aged four to six, extending its current booster-use age range, which starts at 6 years.
The vaccine is designed to protect against tetanus, diphtheria and pertussis, also known as whooping cough. The company said the proposed expansion aims to address a gap in preschool booster immunization and restore antibody levels to a protective range.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.